U.S. Markets closed

Clorox Attains New High

Zacks Equity Research

The Clorox Company’s (CLX) strong revenue generating capabilities, impressive quarterly beats and an upbeat outlook facilitated it to record a new 52-week high for the 2nd time in April.

After attaining a 52-week high of $89.33 on Tuesday, Apr 2, shares of this consumer products company further soared to touch a new high of $89.66 yesterday. Shares eventually closed at $89.53, rising 20.8% year to date. The company currently trades at a forward P/E of 20.6x, at par with the peer group average.

Alongside, companies like Campbell Soup Company (CPB), The Walt Disney Company (DIS) and Colgate-Palmolive Co. (CL) crafted new 52-week highs of $46.54, $60.75 and $119.48, respectively on Tuesday.

Clorox's diversified portfolio of brands positions it well to generate above-average industry growth amid a challenging environment. The company’s rigorous research & development process, marketing strategies, financial control, and operating leverage further strengthen its brands and facilitate it to generate long-term profitability, which is well evident from its record of beating the quarterly earnings expectations.

If we look at the company earnings surprise history, Clorox has surpassed the Zacks Consensus Estimate in the last 9 quarters. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 11.1%.

Going forward, Clorox expects to sustain its growth momentum through market share gains and product innovation. The company raised its sales growth forecast to 3%–5% for fiscal 2013 from 2%–4% projected earlier.

In fiscal 2013, the company expects operating income margin to expand 25–50 basis points (bps) on the back of efficient cost savings, price increases and flat commodity costs. Further, Clorox raised its fiscal 2013 earnings guidance range to $4.25–$4.35 per share from the previous range of $4.20–$4.35.

Currently, shares of Clorox maintain a Zacks Rank #2 (Buy).

Read the Full Research Report on CL

Read the Full Research Report on CPB

Read the Full Research Report on DIS

Read the Full Research Report on CLX

Zacks Investment Research

More From Zacks.com